Phase II Clinical Study to Evaluate the Efficacy and Safety of WX-0593 in Patients With Crizotinib-resistant ALK -Positive, or Crizotinib-resistant/Crizotinib-naive ROS1-positive Non-small Cell Lung Cancer (NSCLC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iruplinalkib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms INTELLECT
Sponsors Qilu Pharmaceutical

Most Recent Events

10 Sep 2024 Results presented in a Qilu Pharmaceutical Media Release.
10 Sep 2024 According to a Qilu Pharmaceutical media release, results of the study were published in BMC Medicine in 2023.
10 Sep 2024 According to a Qilu Pharmaceutical media release, trial is led by principal investigator, Prof. Yuankai Shi from the Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight